Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

PLoS One · 2012 · PMC3470549 · PMID 23174912

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

The difference was apparent in the survival curves for patients with WT KRAS tumours who received anti-EGFR, those with WT KRAS tumours who did not receive an anti-EGFR agent and patients with MT KRAS tumours.

also in 455 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.